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This Editorial highlights a study by Hunsberger et al. (2015) in the current issue of Journal 
of Neurochemistry, in which the authors explore the effects of riluzole treatment on tau 
P301L transgenic mice. The authors employed a comprehensive analysis of possible 
restorative effects of the drug by examining glutamate levels in subregions of the 
hippocampus, expression of tau and its hyper-phosphorylated forms, and memory function 
using behavioral tests. The authors report a simultaneous reduction in glutamate reuptake 
and an increase in glutamate release in the P301L model, both of which are ameliorated 
with riluzole treatment. The authors’ findings have implications for our understanding of 
Alzheimer’s disease pathology. 
 
Both experimental and clinical studies indicate that impaired excitatory synaptic 
transmission, which ultimately culminates in hypoactivity, is a hallmark feature of 
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Alzheimer’s disease (AD) pathology. Intriguingly, studies also find that AD patients have a 
propensity for epileptic seizures, and various in vitro cellular models of AD pathology 
display hyperactive and dyssynchronous network function (Palop and Mucke, 2010). 
Taken together, this suggests the coexistence of hyper- and hypoactivity, which perhaps 
varies by brain region, neuronal subtype and/or stage of disease (Busche and Konnerth, 
2015). Glutamate is the major excitatory neurotransmitter in the brain, and so its 
production, secretion and clearance are all tightly regulated cellular processes. 
Dysregulation of glutamate could be critical in the expression of aberrant network activity 
in AD (Rudy et al., 2015). However, the underlying mechanisms have not yet been 
established. 
 
A key component of AD pathology is a change to the microtubule-associated protein 
(MAP) tau. The protein, which canonically functions to stabilize microtubules, becomes 
hyperphosphorylated in the disease, leading to formation of aggregates termed paired-
helical filaments (PHF), which are considered neurotoxic. Though first thought of as a 
predominantly neuronal axon protein, growing evidence now suggests that tau is also 
present in other subcellular compartments, such as dendritic spines (Kimura et al., 2014), 
as well as in glial cells. Under pathological conditions tau seems to accumulate in 
astrocytes (Berry et al., 2001). However, the physiological role for tau in glial cells is yet to 
be fully characterised. 
 
A number of mutations to the tau gene have been identified as risk factors for hereditary 
tauopathy (Wolfe, 2009). One such is the P301L mutation, which has been explored in 
detail following the generation of a doxycycline-suppressed transgenic mutant mouse 
(SantaCruz et al., 2005). The exact toxicity of this tau mutation may be due to the reduced 
binding affinity with microtubules and a propensity for aggregation (Hong et al., 1998). One 
of the clear advantages of this model is the delayed onset of tauopathy, avoiding potential 
confounding factors that may arise if pathological tau were to be expressed during 
development, and perhaps more closely following the late-onset nature of tauopathy in 
human AD. However, it is important to acknowledge that the P301L model, focusing on tau 
expression, does not consider any significant contribution from amyloid beta, widely 
considered to partner hyperphosphorylated tau in driving AD pathogenesis. Thus, as is the 
case with many transgenic models, findings and interpretations must be caveated. 
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Riluzole (2-amino-6-(trifluoromethoxy) benzothiazole) functions as a sodium channel 
blocker, and is a US Food and Drug Administration-approved disease-modifying drug for 
amyotrophic lateral sclerosis (ALS). A number of studies have now established that 
riluzole exerts anti-glutamatergic effects, through the inhibition of presynaptic glutamate 
release and enhancement of glutamate transporter activity (Fumagalli et al., 2008; Grant 
et al., 2010). Adverse side effects associated with the drug are generally considered 
relatively mild. One of the more frequently reported effects is an increase in levels of 
transaminases. However, given that most clinical data has come from studies with ALS 
patients, and the condition itself is generally fatal, there is currently limited understanding 
of what the possible implications of long-term use of the drug are (Grant et al., 2010). 
 
In this issue, Hunsberger et al. (2015) explore the effects of riluzole treatment on tau 
P301L transgenic mice. The authors employed a comprehensive analysis of possible 
restorative effects of the drug by examining: (i) glutamate levels in subregions of the 
hippocampus, (ii) expression of tau and its hyper-phosphorylated forms, and (iii) memory 
function using behavioral tests. The authors report a simultaneous reduction in glutamate 
reuptake and an increase in glutamate release in the P301L model, both of which are 
ameliorated with riluzole treatment. It remains to be explored whether one of these 
functions is more important than the other in contributing to the pathology of the disease. 
Interestingly, whilst the authors observed an increase in tonic and KCl-induced glutamate 
levels in the P301L mice, this was only present in the CA3 and CA1 regions of the 
hippocampus, not the dentate gyrus, indicative of some regional differences in vulnerability 
to a presumably tau-mediated dysregulation of glutamate processing. Such differences in 
propensity for succumbing to pathological dysregulation have been explored in previous 
studies (Small et al., 2011). Histological studies indicate that the entorhinal cortex is 
severely affected in AD, with similar pervasive cell death noted in the CA1 and subicular 
regions of the hippocampus. However, the CA3 remains relatively unaffected by 
comparison (Small et al., 2011). Relevant to the present study, there is tentative evidence 
(both in animal models and postmortem studies in human patients), for dentate gyrus-
specific resistance to AD-related changes (Small, 2014), though more work is required to 
substantiate this further. 
 
The postsynaptic density protein 95 (PSD-95) forms a multimeric scaffold for the clustering 
of receptors, ion channels and signalling proteins at the postsynaptic density of excitatory 
synapses. Changes in PSD-95 expression can alter the ratio of excitatory to inhibitory 
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synapses. Furthermore, PSD-95 interacts with N-methyl-D-aspartate (NMDA) receptors 
(NMDARs) and is required for NMDAR-mediated synaptic plasticity. The authors report 
that reductions in PSD-95 expression in P301L tau transgenic mouse brains are prevented 
by riluzole treatment. Whilst the normalization of PSD-95 levels is certainly indicative of 
restoration of excitatory synapses, such an assertion cannot really be made until further 
examination of more discrete components of the synapse under these conditions has been 
performed. Changes in, for example, glutamate receptor expression or subunit 
composition have significant impact on synaptic function, and so the capacity for riluzole to 
regulate these will also be of critical importance to consider in the future. 
 
The authors note that trying to understand the mechanisms that mediate the increase in 
tonic and KCl-induced levels of glutamate in the P301L transgenic mice will be carried out 
in future studies. The outstanding question here is a fundamental one; why does the 
expression of a mutant form of tau lead to impaired glutamate processing? Answering this 
question could well be pivotal in our understanding of the links between a developing AD 
pathology and hyperexcitabilty in the brain. Growing evidence is beginning to outline novel 
physiological roles for tau in neurons, particularly in the regulation of excitatory synaptic 
transmission (Kimura et al., 2014; Regan et al., 2015). Perhaps in addition to these, tau 
also forms part of the glia-based mechanism responsible for glutamate processing, for 
example regulating the expression and/or function of glutamate transporters. Indeed, there 
is some tentative evidence to suggest that tau interacts with excitatory amino acid 
transporter 2 (EAAT2) in human AD brain tissue (Sasaki et al., 2009). Further work will 
now be required to assess the components of the glutamate regulating system that tau 
interacts with, both physiologically and pathologically. 
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Fig. 1. Schematic representation of riluzole effects on tau-induced changes at 
hippocampal glutamatergic synapses. Riluzole (R) counteracts the P301L tau 
expression (Tau-P301L)-induced increase in glutamate release, decrease in glutamate 
uptake and reduction in PSD-95 levels at hippocampal synapses (based on Hunsberger et 
al., 2015). EAAT2, excitatory amino acid transporter 2; NMDAR, N-methyl-D-aspartate-
type ionotropic glutamate receptor; PHF, paired-helical filaments; PSD, post-synaptic 
density; PSD-95, post-synaptic density protein 95; vGLUT1, vesicular glutamate 
transporter 1. See text for details. 
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